RFA-DA-25-049: Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to small businesses. Applications closed on December 2, 2024.
From the official notice on Grants.gov, last changed June 13, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR41 / R42
- Clinical trialsOptional
- Funded byNIDA
- Median yearly award$399,889
- Typical project length1 year
- R41, Small Business Technology Transfer (STTR) Phase I. A small business and a research institution test the feasibility of a technology together. Other open R41 notices.
- R42, Small Business Technology Transfer (STTR) Phase II. Full development of an STTR project after Phase I. Other open R42 notices.
Projects funded under RFA-DA-25-049 were run by National Institute on Drug Abuse (NIDA, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-25-049 in the NIH Guide.
Key dates
| Posted | June 13, 2024 |
|---|---|
| Deadline | December 2, 2024 |
| Archived by Grants.gov | January 7, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This funding opportunity calls for developing novel solutions targeted to improve health outcomes and reduce the impact of adverse health consequences in people who use drugs. These solutions should maximize accessibility and affordability, ideally designed to be implemented in mobile community-based care systems and able to reach the vulnerable and underserved population with limited engagement with conventional healthcare services. Solutions could be based on original technologies or existing technologies already available that could be repurposed to target the specific needs of people who use drugs.
Funded under RFA-DA-25-049 so far
NIH funded 3 projects under RFA-DA-25-049 in fiscal 2026, at 3 institutions. The median yearly award was $399,889.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Treatment of CNS damage from non-disordered drug use with DRhQ, a novel regulator of CD74 signaling | Virogenomics Biodevelopment, Inc. | 2026 | $399,889 |
| Targeting novel translation mechanism to treat NFOO-induced hypoxia-related brain injuries | Transchromix, LLC. | 2026 | $399,994 |
| Chimectin as a novel wound biologic for xylazine-induced tissue injury | Edi Therapeutics LLC | 2026 | $274,219 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-25-049 still open?
No. It closed on December 2, 2024.
Who can apply for Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)?
Closed December 2, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-DA-25-049?
NIH RePORTER lists 3 projects funded under RFA-DA-25-049 in fiscal 2026, at 3 institutions. The most were at Virogenomics Biodevelopment, Inc., Transchromix, LLC., Edi Therapeutics LLC.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)